Whole Live Micro-organism, Cell, Or Virus Containing Patents (Class 424/93.1)
  • Patent number: 11110154
    Abstract: Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: September 7, 2021
    Assignees: Sangamo Therapeutics, Inc., CHDI Foundation, Inc.
    Inventors: Steven Froelich, Seung Kwak, Ignacio Munoz-Sanjuan, H. Steve Zhang
  • Patent number: 11103582
    Abstract: Materials and methods for treating a patient to express a therapeutic agent comprising administering a Kupffer cell-suppressing substance in combination with a vehicle for introducing, into the patient, an exogenous nucleic acid comprising a sequence for expression of the agent.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: August 31, 2021
    Assignee: IMMUSOFT CORPORATION
    Inventors: R. Scott McIvor, Perry B. Hackett, Jason Bell, Myra Christine Urness-Rusten, Elena Aronovich, David W. Hunter
  • Patent number: 11090339
    Abstract: Provided herein are methods of treatment of an individual having pain, e.g., neuropathic pain, comprising administering to the individual a therapeutically effective amount of tissue culture plastic adherent placental stem cells (PDAC™).
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Celularity Inc.
    Inventors: Uri Herzberg, Jodi P. Gurney, Robert J. Hariri
  • Patent number: 11090332
    Abstract: Disclosed are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mRNA encoding said immunogenic epitopes. In one embodiment of the invention, said modified mRNA encodes peptides derived from the protein survivin. By directly inducing gene expression of the antigens to which an immune response is desired, immunogenic peptides are generated intracellularly, thus allowing for a wider repertoire of epitopes to be presented to the adaptive immune system, which augments likelihood of successful induction of immunity.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: August 17, 2021
    Assignee: Regen Biopharma, Inc.
    Inventors: David Koos, Thomas Ichim
  • Patent number: 11072780
    Abstract: Methods for generating high-yield, high-purity cardiac fibroblasts are described. Differentiation methods comprising chemically defined culture conditions and methods for in vitro maintenance of human pluripotent stem cell-derived cardiac fibroblasts are also provided.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 27, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Timothy Joseph Kamp, Jianhua Zhang
  • Patent number: 11058729
    Abstract: Methods are disclosed herein for treating glaucoma in a subject. In some embodiments, the methods increase retinal ganglion cell survival. The disclosed method use exosomes and/or miRNA.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: July 13, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stanislav Ivanovich Tomarev, Benjamin Frank John Martin Mead
  • Patent number: 11052118
    Abstract: The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of enhanced hematopoietic stem and progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic compositions. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 6, 2021
    Assignee: Fate Therapeutics, Inc.
    Inventors: Daniel Shoemaker, David Robbins, John D. Mendlein, Caroline Desponts
  • Patent number: 11027013
    Abstract: The present invention concerns a pharmaceutical composition where a checkpoint inhibitor is combined with an oncolytic virus and the use of said combination for the treatment of cancer.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: June 8, 2021
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
    Inventors: Barbara Leuchs, Antonio Marchini, Jean Rommelaere, Assia Angelova, Dirk Jager, Wolfgang Wick, Michael Dahm
  • Patent number: 11027024
    Abstract: The present disclosure provides methods of treating a disease or delivering a therapeutic agent to a mammal comprising administering to the mammal's deep cerebella nuclei a recombinant adeno-associated virus (rAAV) particle comprising an AAV capsid protein and a vector comprising a nucleic acid encoding a therapeutic agent inserted between a pair of AAV inverted terminal repeats in a manner effective to infect the CNS cell of the non-rodent mammal such that the CNS cell expresses the therapeutic agent in the non-rodent mammal.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: June 8, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Beverly L. Davidson, Megan S. Keiser
  • Patent number: 11014975
    Abstract: Factor VIII variants and methods of use thereof are disclosed. In particular embodiments, Factor VIII variants are expressed more efficiently by cells over wild-type Factor VIII proteins, are secreted at increased levels by cells over wild-type Factor VIII proteins, exhibit enhanced activity over wild-type Factor VIII proteins and are packaged more efficiently into viral vectors.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: May 25, 2021
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Denise Sabatino, Katherine A. High, Liron Elkouby
  • Patent number: 10993443
    Abstract: Provided herein are isolated yield enhancing Methylobacterium sp., compositions comprising yield enhancing Methylobacterium sp., methods of using the compositions to increase yield of soybean plants, plant parts, and soybean plants derived therefrom, and methods of making the compositions. Such yield enhancing Methylobacterium sp. are in certain instances referred to herein as simply “Methylobacterium”. In certain embodiments, yield enhancing Methylobacterium sp. can be distinguished from other yield neutral or yield negative Methylobacterium by assaying the Methylobacterium sp. for improved yield in a controlled environment (i.e. a growth chamber or greenhouse) or in a field test in comparison to untreated control plants.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: May 4, 2021
    Assignee: NewLeaf Symbiotics, Inc.
    Inventors: Marcus Jones, Gregg Bogosian
  • Patent number: 10973898
    Abstract: The present invention is directed to a method of treating poultry hatchlings in a hatchling tray. The method comprises of providing a soft gel form capable of being dispensed through a spray nozzle, providing a spray dispensing apparatus, the apparatus being capable of delivering a predetermined volume of the gel as a plurality of small beadlets through a plurality of nozzles, placing the hatchling tray containing the hatchlings beneath the nozzles of the dispensing apparatus, dispensing the predetermined volume of the soft gel containing the therapeutic agent as small beadlets into the hatchling tray and allowing the hatchlings to consume the beadlets. The present invention is also directed to a dispensing apparatus for dispensing a therapeutic agent in a soft gel into a hatchling tray of poultry hatchlings.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: April 13, 2021
    Assignee: CEVA ANIMAL HEALTH INC.
    Inventor: Eng-Hong Lee
  • Patent number: 10973956
    Abstract: The present disclosure relates generally to biomaterial implants and methods for delivering a cell to an individual in need thereof and, more particularly, to biomaterial implants and techniques for delivering islets and/or ?-cell progenitors to an individual.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Tadas Kasputis, Michael Skoumal, Lonnie D. Shea
  • Patent number: 10960074
    Abstract: A process for treating glaucoma whereby the treatment can be accomplished by the use of medication or by surgery, or both, in order to control or prevent the occurrence of glaucoma. The optic nerve is aligned within and between two distinct pressurized spaces and within the dural sheath, the intraocular space and the intracranial space having an intraocular pressure (IOP) and an intracranial pressure (ICP), respectively. Medicine can be administered to raise the intracranial pressure in order to reach a desirable lower translaminar pressure difference across these two pressurized spaces which are separated by the lamina cribrosa in order to treat glaucoma. An alternate closely related mode of the treatment process is the implanting of a shunt substantially between the intraocular space and the intracranial space in order to beneficially equalize pressure differentials across the intraocular space and the intracranial space.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: March 30, 2021
    Inventor: John Berdahl
  • Patent number: 10918738
    Abstract: In alternative embodiments, the invention provides methods for treating, ameliorating or protecting (preventing) an individual or a patient against a disease, an infection or a condition responsive to an increased paracrine polypeptide level in vivo comprising: providing a paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence; or an expression vehicle, a vector, a recombinant virus, or equivalent, having contained therein a paracrine-encoding nucleic acid or gene, and the expression vehicle, vector, recombinant virus, or equivalent can express the paracrine-encoding nucleic acid or gene in a cell or in vivo; and administering or delivering the paracrine polypeptide-encoding nucleic acid or gene operatively linked to a transcriptional regulatory sequence, or the expression vehicle, vector, recombinant virus, or equivalent, to an individual or a patient in need thereof, thereby treating, ameliorating or protecting (preventing) the individual or patient a
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: February 16, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: H. Kirk Hammond, Mei Hua Gao
  • Patent number: 10894946
    Abstract: The invention is directed to a method for the preparation of a multiring engineered heart tissue construct suitable for use in cardiac tissue augmentation and/or replacement therapy. The invention further refers to multiring EHT constructs which comprise at least two force-generating engineered heart tissue rings fused with each other and a device for preparing the same. Finally, the invention relates to force-generating engineered heart tissue rings derived from human cells and their use in drug screening and target validation assays.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: January 19, 2021
    Assignee: Tissue Systems Holding GmbH
    Inventors: Wolfram-Hubertus Zimmermann, Thomas Eschenhagen
  • Patent number: 10842857
    Abstract: Methods of reducing the likelihood of a cancer or precancer developing resistance to a cancer therapeutic or prevention agent are provided herein. The methods include administering a vaccine comprising a polynucleotide encoding a polypeptide whose expression or activation is correlated with development of resistance of the cancer or precancer to the cancer therapeutic or prevention agent to a subject. The vaccine may include a polynucleotide encoding a HER2 polypeptide or a truncation, deletion or substitution mutant thereof. Methods of using the vaccine including the polynucleotide encoding the HER2 polypeptide to treat a cancer or precancer are also provided. The vaccines may be administered with a cancer therapeutic or prevention agent or a checkpoint inhibitor immunomodulatory agent.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 24, 2020
    Assignee: DUKE UNIVERSITY
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Patent number: 10834942
    Abstract: The invention is directed to compositions and methods are disclosed for improving production of swine. In one embodiment the composition may include a combination of at least one of a biologically pure culture of Bacillus strains. The composition may comprise a Saccharomyces cerevisiae yeast product. Methods are disclosed for providing beneficial effects to swine and their offspring, including but not limited to improved performance of the swine.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 17, 2020
    Assignee: Church & Dwight Co., Inc.
    Inventors: Mari Ellen Davis, Kim Friesen, Thomas G. Rehberger, Ran Song
  • Patent number: 10828336
    Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: November 10, 2020
    Assignee: Northern Therapeutics Inc.
    Inventor: Duncan John Stewart
  • Patent number: 10801015
    Abstract: The present invention features assays for co-culturing primary cells while maintaining key biological activities specific to the primary cells. The invention is based, at least in part, on the discovery that compositions and methods for primary cells in a high-throughput co-culture platform, image analysis for distinguishing cells in co-cultures and assays that are suitable for screening of agents in epithelial cells, such as hepatocytes.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 13, 2020
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Sangeeta Bhatia, Jing Shan, Anne Carpenter Van Dyk, David Logan, Nathan Ross
  • Patent number: 10792353
    Abstract: Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: October 6, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Thomas S. Vedvick, Bryan Steadman, Charles Richardson, Thomas R. Foubert, Charles R. Petrie
  • Patent number: 10779519
    Abstract: The present invention is directed to a method of assessing in vivo human glial cell response to pathogenic infection that involves providing a non-human mammal either with at least 30% of its glial cells in its corpus callosum being human glial cells and/or with at least 5% of its glial cells its brain and brain stem white matter being human glial cells, subjecting the non-human mammal to pathogenic infection and assessing the in vivo human glial cell response to pathogenic infection. A method of identifying therapeutic agents for the pathogenic infection as well as forms of the non-human mammal having a pathogenic brain infection are also disclosed.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 22, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Steven A. Goldman, Martha Windrem
  • Patent number: 10772333
    Abstract: A composition and methods of using the composition for the control of mollusks are provided, which include an effective amount of one or more isolated Phasmarhabditis nematodes, wherein at least one of the isolated nematodes is P. californica, P. papillosa or P. hermaphrodita, and wherein the P. hermaphrodita does not comprise Moraxella osloensis.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Irma Tandingan De Ley, Rory McDonnell, Timothy Paine
  • Patent number: 10758655
    Abstract: This document discusses, among other things, systems and methods to reduce ischemic or metabolic injury to a patient's heart. A system to reduce ischemic or metabolic injury to a patient's heart may include a pulse generator for generating electrical pulses or shock, a pacing lead with at least one pacing electrode configured to deliver electrical pulses received from the pulse generator to the patient's heart, a controller configured to control timing of electrical pulses to reduce wall stress of the heart, and a reservoir, fluidically coupled to a lumen and a pump, wherein the pump is configured, under control of the controller, to move contents from the reservoir through the lumen to an area of the heart with the reduced wall stress, wherein the contents include autologous respiration-competent mitochondria or other respiratory-promoting agents.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: September 1, 2020
    Assignee: Cardiac Pacemakers, Inc.
    Inventors: Barbara Ann Huibregtse, Thomas John Herbst, Craig Stolen, Eric M. Schneider, Lynne E. Swanson, Lili Liu
  • Patent number: 10736922
    Abstract: Disclosed are isolated human bone marrow mesenchymal stem cells having high telomerase activity (tBMMSCs). Also disclosed are isolated human CD34+ bone marrow mesenchymal stem cells. Also disclosed are bone marrow mesenchymal stem cells treated with a telomerase induction agent.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 11, 2020
    Assignee: University of Southern California
    Inventors: Songtao Shi, Kentaro Akiyama, Chider Chen
  • Patent number: 10731136
    Abstract: The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or ongogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, said gene being selected among the group comprising E1B55kDa, E4orf6, E4orf3, and E3ADP.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 4, 2020
    Inventor: Per Sonne Holm
  • Patent number: 10695404
    Abstract: Methods of using FGF1 analogs, such as FGF1 mutant proteins having an N-terminal deletion, point mutation(s), or combinations thereof, to reduce blood glucose levels in subjects with steroid-induced diabetes, hypercortisolemia, or diabetes due to treatment with an antipsychotic agent, are provided. Such mutant FGF1 proteins can be part of a chimeric protein that includes a ?-Klotho-binding protein, an FGFR1-binding protein, a ?-Klotho-binding protein and a FGFR1-binding protein, a C-terminal region from FGF19 or FGF21.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 30, 2020
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Annette Atkins, Ruth T. Yu
  • Patent number: 10688151
    Abstract: The invention relates to a peptide, polypeptide, or protein that binds specifically to cells of the lung endothelium. The peptide, polypeptide, or protein can be a component of a viral capsid and can be used to lead a recombinant viral vector selectively to the lung endothelial tissue after systemic administration to a subject and to ensure tissue-specific expression of one or more transgenes there. The invention thus further relates to a recombinant viral vector, preferably an AAV vector, which comprises a capsid comprising the peptide, polypeptide, or protein according to the invention and which comprises at least one transgene packaged in the capsid. The viral vector is suitable in particular for the therapeutic treatment of a lung disorder or a lung disease. The invention further relates to cells and pharmaceutical compositions which comprise the viral vector according to the invention.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: June 23, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Trepel, Jakob Koerbelin, Stefan Michelfelder
  • Patent number: 10676747
    Abstract: An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: June 9, 2020
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORP. LTD.
    Inventors: Kobi Rosenblum, Akiva Rappaport
  • Patent number: 10669526
    Abstract: The present disclosure relates to stem cells derived from a pure chorionic trophoblast layer (chorionic trophoblast layer without villi, CT-V), which is a part of the tissues of the placenta, and cell therapy comprising same. Stem cells derived from a pure chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristics compared to the conventional stem cells derived from the whole placenta, and particularly, exhibit excellent differentiation into cartilage cells, thus can be effectively used in cell therapy for treating cartilage damage, deficiency and such, and as a composition for tissue regeneration.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: June 2, 2020
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Chul Won Ha, Jin A. Kim
  • Patent number: 10639336
    Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: May 5, 2020
    Assignee: GENMONT BIOTECH INCORPORATION
    Inventors: Yi-Hsing Chen, Wan-Hua Tsai, Shiang-Suo Huang, Yi-Hsin Wang
  • Patent number: 10640750
    Abstract: The present invention is directed to methods of inducing spatial organization of cells an in vitro culture system using ultrasound technology. The invention is further directed to methods of inducing extracellular matrix remodeling and neovessel formation in an in vitro culture system and generating vascularized engineered tissue constructs using ultrasound technology.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 5, 2020
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Diane Dalecki, Denise Hocking, Kelley Garvin
  • Patent number: 10631974
    Abstract: The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and/or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: April 28, 2020
    Assignee: AVITA MEDICAL LTD
    Inventors: Fiona M. Wood, Marie L. Stoner
  • Patent number: 10613084
    Abstract: Herein is provided a method that provides a patient, suspected of having Lyme disease, a kit that does not require specialized equipment and allows for easy self-collection of specimens. Methods provided herein, allow for the efficient culturing of Borrelia spirochetes, such as B. burgdorferi spirochetes after being exposed to an environment that is typically not suitable for Borrelia growth.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 7, 2020
    Inventors: Marianne Middelveen, Raphael Stricker
  • Patent number: 10583220
    Abstract: A biocompatible, bioresorbable tissue repair implant or scaffold device is provided for use in repairing a variety of cartilage tissue injuries, and particularly for resurfacing and/or repairing damaged or diseased cartilage. The repair procedures may be conducted with tissue repair implants that contain a biological component that assists in delaying or arresting the progression of degenerative joint diseases and in enhancing tissue healing or repair. The biocompatible, bioresorbable tissue repair implants include a scaffold and particles of viable tissue derived from cartilage tissue, such that the tissue and the scaffold become associated. The particles of living tissue contain one or more viable cells that can migrate from the tissue and populate the scaffold.
    Type: Grant
    Filed: August 11, 2003
    Date of Patent: March 10, 2020
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Francois Binette, Ed Yiling Lu
  • Patent number: 10584355
    Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: March 10, 2020
    Assignees: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Nancy J. Sullivan, Gary J Nabel, Clement Asiedu, Cheng Cheng, Alfredo Nicosia, Riccardo Cortese, Virginia Ammendola, Stefano Colloca
  • Patent number: 10576106
    Abstract: The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 3, 2020
    Assignee: Cellatoz Therapeutics, Inc.
    Inventor: Myung-Kwan Han
  • Patent number: 10563226
    Abstract: Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: February 18, 2020
    Assignee: Seattle Children's Hospital
    Inventors: Andrew Scharenberg, David Rawlings, Michael C. Jensen, Kamila Gwiazda, Alexandra Grier
  • Patent number: 10538742
    Abstract: This invention relates to the methods for the identification and isolation of cancer stem cells from cultured cancer cell lines. Cell line-derived cancer stem cells isolated using the present methods may be useful, for example, in assays to screen compounds for anti-cancer stem cell activity and in target discovery methods for identifying novel expressed genes and druggable targets. The invention also relates to the screening of compounds for activity against cell line-derived cancer stem cells.
    Type: Grant
    Filed: November 12, 2005
    Date of Patent: January 21, 2020
    Assignee: Cambridge Enterprise Limited
    Inventor: Toru Kondo
  • Patent number: 10526577
    Abstract: Disclosed are genetically modified human pancreatic progenitor cells having an exogenous nucleic acid molecule encoding TGIF2, for use as a medicament in the treatment of a subject with diabetes. In addition methods for the production of such cells are described. Also disclosed is an expression vector encoding TGIF2 for use as a medicament in the treatment of a subject with diabetes.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: January 7, 2020
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN
    Inventors: Francesca Spagnoli, Nuria Cerda-Esteban
  • Patent number: 10514163
    Abstract: The technology relates in part to methods and compositions for ex vivo proliferation and expansion of epithelial cells.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: December 24, 2019
    Assignee: PROPAGENIX INC.
    Inventor: Chengkang Zhang
  • Patent number: 10507225
    Abstract: The present disclosure relates to the field of health care products. The present disclosure provides a powder which is prepared from xylooligosaccharide, isomaltooligosaccharide, mannitol, inulin, RADIX CODONOPSIS, FRUIT BODY HERICIUM ERINACEUS extract, RHIZOMA DIOSCOREA OPPOSITA, SCLEROTIUM PORIA, SEMEN DOLICHOS, PERICARPIUM CITRUS, FRUCTUS AMOMUM and RHIZOMA MACROCEPHALA. All raw materials are from natural Chinese herbal medicine. No additives are added. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. Experiment data shows that the powder described in the present disclosure has the function of relieving the gastric mucosal injury by reducing the acute gastric mucosal injury induced by ethanol effectively and has the function of regulating gastric mucosa.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: December 17, 2019
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Lei Wang, Ruiqi He, Hongwei Zhao, Qingtao Tang
  • Patent number: 10501756
    Abstract: The present invention relates to a gene therapy vector which is useful in the treatment or prevention of hypertrophic cardiomyopathy in a subject in need thereof. The gene therapy vector of the invention comprises a nucleic acid sequence encoding a cardiac sarcomeric protein and a cardiomyocyte-specific promoter which is operably linked to said nucleic acid sequence. The invention furthermore relates to a cell which comprises the gene therapy vector. Pharmaceutical compositions which comprise the gene therapy vector and/or a cell comprising said vector are also provided. In another aspect, the invention relates to a method for treating or preventing hypertrophic cardiomyopathy in a subject by introducing the gene therapy vector of the invention into a subject in need of treatment.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: December 10, 2019
    Assignees: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG, SORBONNE UNIVERSITÉ, ASSOCIATION INSTITUTE DE MYOLOGIE
    Inventors: Lucie Carrier, Thomas Eschenhagen, Thomas Voit, Giulia Mearini, Oliver Mueller, Doreen Stimpel, Julia Mourot-Filiatre
  • Patent number: 10494607
    Abstract: Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45? stem cells from placenta.
    Type: Grant
    Filed: February 12, 2008
    Date of Patent: December 3, 2019
    Assignee: CELULARITY, INC.
    Inventors: James W. Edinger, Robert J. Hariri, Jia-Lun Wang, Qian Ye, Marian Pereira, Sascha Dawn Abramson, Kristen S. Labazzo
  • Patent number: 10493104
    Abstract: The present invention relates to a composition for treating inflammatory brain diseases which includes a stem cell as an active ingredient. When the stem cell according to the present invention is directly administered to animal models with inflammatory brain diseases, a brain damage caused by inflammation such as edema is significantly reduced, the weight-loss phenomenon is greatly improved, and the like, and thus the cell has an excellent effect in treating inflammatory brain diseases and consequently can be used effectively in treating inflammatory brain diseases.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: December 3, 2019
    Assignee: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Yun Sil Chang, Won Soon Park
  • Patent number: 10464994
    Abstract: Recombinant clusterin polypeptides and compositions comprising the same are provided. In some aspects, recombinant clusterin or nucleic acids encoding the same may be used for treating and preventing an abnormality of morphology and function in a mammal with disease (e.g., cardiovascular diseases or alcoholism).
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: November 5, 2019
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Yong-Jian Geng
  • Patent number: 10443106
    Abstract: The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: October 15, 2019
    Assignee: Advatect Diagnostics, LLC
    Inventor: Dennis G. Hooper
  • Patent number: 10435732
    Abstract: The present invention provides a method for producing a recombinant protein, which can increase the cell growth rate in culture while stably maintaining plasmids in the cells, thereby improving the recombinant protein yield. The present invention provides a method for producing a recombinant protein, including a high-temperature culture step of culturing at 32° C. or higher a Brevibacillus bacterium that contains a gene encoding a recombinant protein, and a low-temperature culture step of culturing the Brevibacillus bacterium at a temperature lower than 32° C. after the high-temperature culture step.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: October 8, 2019
    Assignee: KANEKA CORPORATION
    Inventors: Hiroyuki Kanamaru, Teruaki Takesue, Osamu Odawara, Takeyuki Tsuchidate
  • Patent number: 10426826
    Abstract: The present invention relates to a Shigella strain, of which the surface exposure of a protective antigen existing on a cellular membrane is increased due to the destruction of a wzy gene of Shigella sp., and to a vaccine composition for treating or preventing shigellosis, containing the mutant Shigella strain as an active ingredient. The Shigella strain of the present invention has a cell wall with a reduced thickness since a gene encoding a protein necessary for polymerization of the O-saccharide antigen is deleted, and as a result, membrane antigens including protein antigens commonly existing in different Shigella spp. are more exposed to immune cells, and thus the Shigella strain can be favorably used as a vaccine composition for treating or preventing shigellosis, derived from various Shigella spp.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: October 1, 2019
    Assignee: International Vaccine Institute
    Inventors: Jae Ouk Kim, Min Jung Kim, Man Ki Song
  • Patent number: 10392632
    Abstract: This application relates to the fields of gene therapy and molecular biology. In accordance with the present invention, an adeno-associated virus (AAV) vector comprising an altered capsid protein is provided. More specifically, this invention provides adeno-associated viral vectors comprising protein capsid variants which accelerate vector breakdown and clearance, thereby reducing undesirable immune responses.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: August 27, 2019
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: John Fraser Wright, Olga Zelenaia, Bernd Hauck, Federico Mingozzi, Katherine A. High